预约演示

AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again

2024-04-26

临床结果上市批准临床3期

In a head-to-head trial, AbbVie's Rinvoq showed superior efficacy over Regeneron and Sanofi's Dupixent in patients with moderate-to-severe atopic dermatitis.

For the second time in foAbbViers,Rinvoqe’s Rinvoq (upadacitinib) has sRegeneronrior Sanoficy Dupixenteron and Sanofi’s powerhouse Dupixentatopic dermatitis head-to-head study in patients with atopic dermatitis (AD).

In the LEVEL UP trial testing patieAbbViee 1Rinvoqolupadacitiniberate-to-severe AD who had an inaRegeneronesponSanofisystemic theraDupixentofdupilumab Rinvoq achieved nearly complete skin clearatopic dermatitis (AD) itch after 16 weeks, compared to 9% of those on Dupixent. AbbVie’s anti-inflammatory treatment also conquered Dupixent in all secondary objectives of the phase 3b/4 study.

For the primary endpoint, the standard of comparison was determining the number of patients who achieved a 90% or greater reduction on the Eczema Area Rinvoqverity Index (EASI) and attained a 0 or 1 grade on the Worsitchuritis Numerical Rating Scale (WP-NRS). EASIDupixentprAbbVietool used to determine the severity of AD whilDupixent measures itch on a 0-10 scale.

“Even while receiving conventional treatments, many patients with atopic dermatitis still continue to live with significant itch and inflamEczema skin symptoms that can profoundly impact their everyday lives,” Roopal TPruritisM.D., AbbVie’s chief medical officer, global therapeutics, said in a release. “Results from this study show that patieitchwith moderate-to-severe atopic dermatitis can strive for both little to no itch and clearer skin.”

Dupixent, which works by inhibiting signaling of both IL-4 and IL-atopic dermatitisto treat AD, its first of five indicationitchack iinflammatory skin symptomsoq meanwhile reached the market in 2019 to treat rheumatoid arthritis. ItAbbVieoval for AD came in 2022, which is one of seven indications for which it is endorsed. AD is the only disorder for which both are approatopic dermatitisnt’s label has been expanded to tritchAD patients 6 months and older, Rinvoq’s approval is limited to those age 12 and older.

Dupixent0 stage 3b trial, Rinvoq conquered Dupixent inIL-4 withIL-13of patients achieving a 75% reduction in EASI compared to 61% for DupixenJAK inhibitor JAKfter 16 weeRinvoqnvoq also came out on top in secondary endpointrheumatoid arthritishe study was overshadowed by the death of one of the patients who was treated with the JAK inhibitor.Dupixent Rinvoq

In that trial, Rinvoq was Rinvoqed in a 30 Dupixent In the recent study, patients started with a 15 mg dose which was adjusted up to 3Dupixented on clinical reRinvoq. There were no new safety signals identified in LEVEL UP.JAK inhibitor JAK

While Rinvoq isRinvoqly oral medication, Dupixent is self-injected, starting with a 600 mg dose for adults, followed by 300 mg doses every two weeks.

“Too mRinvoqtients are still not achievinDupixentl disease control in atopic dermatitis despite taking steps to manage their condition,” Jonathan Silverberg, M.D., Ph.D., MPH, professor of dermatology at the George Washington University School of Medicine and Health Sciences, said in the release. “Results from the LEVEL UP study highlight how treatment options such as upadacitinib can achieve high treatment goals in atopic dermatitis.”

With sales of $4 billion in 2023, Rinvoq has combined with Skyrizi, whatopic dermatitis billion last year, to provide AbbVie with a pair of newer immunology drugs that are helping the company compensate for the loss of patient protection for Humira, whose sales peaked at $21.2 billion in 2022.upadacitinib atopic dermatitis

Dupixent however generated megabloRinvoqer sales of $11.6 bSkyriziin 2023 and is on the verge of a potentially lucratiAbbVieroval to become the first biologic treatment for chronic obstructive pulmonary disease (COPD). Evercore ISI analyst JoHumiraimmer has projected Dupixent’s sales potential at more than $20 billion by the end of this decade as it looks to match the might of Humira's glory days.